Don’t want emails from us anymore? Click here to unsubscribe.

A rare-disease drugmaker is soaring after a successful late-stage trial for its obesity therapy, tech stocks continue to tank in the aftermath of new tariffs, and a bakery chain is up 140%+ after posting strong profits in its China operations. Read on to find out more.

Disruptive Tech (Sponsored)

Urgent Event with Jeff Brown: The Robotaxi Emergency Briefing

Elon Musk’s created a whole group of “Teslanaires”... His companies are worth more than $2 trillion combined... And the small companies connected to his breakthroughs have soared.

Now, as early as June 1, Tesla is set to launch its initial fleet of self-driving robotaxis —  and Elon believes what’s coming could create “the biggest asset value appreciation in history.”

When you click the link, your name will automatically be added to Jeff’s guest list.)

Silicon Valley insider Jeff Brown’s sharing all the details in The Robotaxi Emergency Briefing – including the name of one of his top picks.

Click here to register with a single click.

(When you click the link, your name will automatically be added to Jeff’s guest list.)

Futures 📈

What to Watch

Earnings:

Economic Reports:

Clean Energy (Sponsored)

On Behalf of Azincourt Energy Corp

A Tiny Uranium Stock That Could Soar Like UEC

Five years ago, Uranium Energy Corp. (UEC) was a small uranium junior trading at just $0.60.

Most investors ignored it.

Then, the uranium market exploded.

UEC’s stock skyrocketed 2,500 percent, transforming early investors into millionaires.

Now, the market is hunting for the next UEC.

One tiny uranium junior is sitting on prime assets in the world’s richest uranium region.

Drill results confirm uranium mineralization, with more exploration underway.

Global nuclear expansion is fueling long-term demand for uranium.

The US is desperate for domestic uranium supply—creating a major opportunity.

With billionaire-backed nuclear investments and a global energy crunch, this company could be the next big uranium success story.

Find out why investors are paying attention to this stock.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Markets

Global Markets Plunge $9.5 Trillion - Tesla, NVIDIA, Apple, Amazon All Down

Financial markets are in free fall this morning, as investor anxiety over President Trump’s tariff escalation triggers one of the steepest selloffs in recent years.

Global equity markets have now lost approximately $9.5 trillion in value over the past three trading sessions, with U.S. futures pointing to continued losses.

The S&P 500 is poised to open 3% lower, while the Nasdaq 100 has tumbled 16% in just six weeks.

The so-called "Magnificent Seven" stocks have dropped by 20% over the same period.

Tesla shares are down over 6% in premarket trade today, NVIDIA is down 5%, and Apple, Amazon, and Citigroup each have lost about 3%.

President Trump, speaking aboard Air Force One, doubled down on the tariff strategy, telling reporters to "forget markets for a second," despite recession warnings from top economists and criticism from key supporters.

The VIX volatility index has surged past 50, signaling extreme market fear. Analysts now price in five Fed rate cuts for the year and a 40% chance of an emergency cut within the next week.

Meanwhile, European and Asian stocks have suffered sharp declines, with Germany’s DAX plunging nearly 10% intraday and Hong Kong’s Hang Seng down 13%.

Strategists warn that unless policy direction changes, a recession-triggered market correction could deepen in the weeks ahead.

Pharmaceuticals

Rhythm Pharma Reports Major Win in Obesity Drug Trial with Nearly 20% BMI Drop

Rhythm Pharmaceuticals (NASDAQ: RYTM) announced that its Phase 3 TRANSCEND study has successfully met its main objective in patients with acquired hypothalamic obesity, a rare and difficult-to-treat condition.

The trial, which involved 120 participants, demonstrated that the company’s lead candidate, setmelanotide, produced a placebo-adjusted body mass index (BMI) reduction of 19.8%.

The therapy led to a 16.5% average BMI reduction among all patients in the study and, in adults specifically, achieved a placebo-adjusted drop of 19.2%. No new safety concerns were reported during the trial.

With these promising results, Rhythm plans to submit regulatory applications in both the United States and European Union by the third quarter of this year.

If approved, setmelanotide could become the first targeted treatment for acquired hypothalamic obesity, a condition that stems from damage to the hypothalamus—often caused by tumors, surgery, or injury—and leads to uncontrollable weight gain.

Shares of Rhythm Pharmaceuticals are up 4.8% in early trading.

The company views the outcome as a key step toward addressing a significant unmet need in rare metabolic disorders and says it will continue to assess long-term outcomes as part of its ongoing development strategy.

Momentum Stock Watch (Sponsored)

This Could Be the Fastest Way to Catch a Breakout Stock

Markets move fast—and the biggest gains often go to those who act first. That’s why thousands of traders are already tuning in to these real-time alerts for stocks with serious upside potential.

(By clicking any of the links above, you agree to receive emails from GuyStocks. You can opt out at any time. - Privacy Policy)

No fluff. No fees. Just hot stocks delivered straight to your inbox—before the crowd catches on.

The next alert could be just around the corner.

[Click here to get on the list and don’t miss what’s next.]

(By clicking any of the links above, you agree to receive emails from GuyStocks. You can opt out at any time. - Privacy Policy)

Medical Devices

ReShape Lifesciences Posts Smaller Loss, Seeks Stability Through Vyome Merger as Shares Rise

ReShape Lifesciences (NASDAQ: RSLS) released its full-year 2024 report on Friday, showing progress in cost reduction and product development despite ongoing financial headwinds.

The company posted revenue of $8 million, a 7.7% decline from the prior year, primarily due to the growing popularity of GLP-1 weight loss medications.

Gross profit dipped slightly, while net loss improved to $7.1 million from $11.4 million a year earlier, thanks to lower operational spending.

Shares of the firm are up 6.7% in premarket trade.

The company highlighted several key developments, including the successful launch of its FDA-approved Lap-Band 2.0 FLEX system and its expansion into the Canadian market through a distribution deal.

A new product, the ReShape Obalon Balloon system, is expected to arrive by late 2025, alongside continued work on a neuromodulation device for type 2 diabetes.

ReShape also disclosed plans for a strategic merger with Vyome Therapeutics and a related asset sale to Biorad Medisys.

The transaction aims to shift focus toward immune-inflammatory treatments and unlock cross-border growth opportunities between the U.S. and India.

While the company secured $4.5 million in financing and completed a 1-for-58 reverse stock split, it acknowledged the need for more capital to remain operational beyond the next 12 months.

With regulatory approvals still pending and financial uncertainty looming, ReShape's path forward hinges on successful execution of its upcoming merger and product rollouts.

Chanson International Holding [CHSN] - Last Close: $0.22

Chanson International Holding is a fast-growing bakery and beverage chain operating in China and the U.S.

Its shares are rising 141% in premarket trading today after it reported a strong FY2024 with 5.7% revenue growth, a 26x increase in net income to $0.8 million, and a significant boost in cash reserves to $12.1 million.

Expansion in China, particularly through the addition of 15 new bakery stores, helped offset challenges in the U.S. market.

Mesa Air Group, Inc. [MESA] - Last Close: $0.71

​Mesa Air Group is a regional airline operator in the U.S.

Its shares are rising before the opening bell today as investors react positively to the news that Mesa is merging with Republic Airways, a move that is expected to bring stronger operational scale, cost efficiencies, and increased route coverage.

Lexeo Therapeutics, Inc. [LXEO] - Last Close: $2.34

Lexeo Therapeutics is a clinical-stage gene therapy company developing treatments for serious genetic cardiac and neurological conditions.

Its shares are rising 18% in premarket today after it announced positive interim Phase 1/2 data for its gene therapy candidate LX2006, targeting Friedreich ataxia cardiomyopathy—a severe, life-shortening heart complication of a rare genetic disorder.

AI (Sponsored)

These 10 AI Stocks Could Power the Next Tech Revolution

AI isn’t just a buzzword anymore—it’s the engine behind a new industrial era.

As applications expand across healthcare, finance, and manufacturing, a select group of AI companies is quietly positioning for massive growth.

A new report just revealed the top 10 AI stocks to watch now—before they hit the mainstream.

Want the names driving this next wave?

[Click here to unlock the full list—for free.]

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club